Bessemer Venture Partners is doubling down on its investments in healthcare start-ups enlisting artificial intelligence tools with the launch of a $10 million fund to invest in seed stage companies. Leading the fund are Stephen Kraus, a partner with Bessemer Venture Partners, and Adam Fisher, a partner who serves as the head of investments in Israel and manages the firm’s Herzliya, Israel office, according to a TechCrunch report.
The Deep Health Seed Program will invest $100,000 to $2 million in the companies it targets. The fund’s first investment is Subtle Medical, which focuses on AI applications for radiology images, according to the report.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Earlier this year Bessemer Venture Partners invested in Qventus, a company that automates operational decisions at hospitals, in a move that gave Kraus a seat on the Qventus board of directors. , Kraus talked about the investment and how it fits in with the venture firm’s perspective on AI in healthcare in a blog post on Medium.
Led by Qventus, workflow automation is one of the crucial areas where we are seeing the immediate impact of AI and ML in our healthcare systems. This is a huge step for the company, but also for the healthcare industry.
We believe Qventus will become the leading logistical operating system for hospitals by turning healthcare data into insights, and turning these insights into action.
One corporate venture capital firm that has developed funds that focus on AI is Optum Ventures, which launched a $250 million fund last year.
Photo: Getty Images